[A17-35] Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) – Benefit assessment according to §35a Social Code Book V
Last updated 15.11.2017
Project no.:
A17-35
Commission:
Commission awarded on 03.08.2017 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Chronic hepatitis C
Added benefit not proven for 12 of 13 research questions. Hint of lesser benefit for DAA-naive adult patients with CHC genotype and compensated cirrhosis
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-05 | Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) - Addendum to Commission A17-35 | Commission completed |
Federal Joint Committee (G-BA)
2018-02-15 A G-BA decision was published.